Support Line: 0800 002 9002
General Enquiries: 01223 870008
  »  Kidney Cancer News  »  Major changes to the current Cancer Drugs Fund

Major changes to the current Cancer Drugs Fund

by | May 10, 2016 | Kidney Cancer News

As previously reported, some major changes to the current Cancer Drugs Fund (CDF) are due to be reported this year.

We would like to inform you that the changes have been delayed until July 1, 2016. Part of the CDF changes involve the introduction of a new rapid reconsideration process, where drugs that have previously not been recommended will be reconsidered by NICE. From the drugs used in kidney cancer, the drug everolimus has been put forward for rapid reconsideration. Everolimus was previously appraised and rejected as a second line treatment, so we are Major changes to the current Cancer Drugs Fundpresuming that the drug is again being appraised as a second line treatment. At the beginning of the reconsideration process, drug companies are able to alter the pricing of the drug and new evidence is also invited. Potentially this might alter whether the drug is recommended by NICE. The anticipated publication of this document is February 2017.
Included in the table below are the other two NICE appraisals that are occurring in the near future which involve drugs used in kidney cancer. We will keep you updated about any developments in this area.  For more information on what is planned and why, please read our previous article on the ‘Cancer Drugs Fund changes and what it could mean to you’ here,

Axitinib, everolimus, sorafenib and sunitinib for treated advanced or metastatic renal cell carcinoma [ID897] Anticipated publication date: TBC
Renal cell carcinoma – everolimus (review of TA219) [ID1015] – CDF rapid reconsideration process Anticipated publication date: February 2017
Renal cell carcinoma (metastatic, treated) – nivolumab [ID853] Anticipated publication date: October 2016
<a href="" target="_self">Malcolm Packer</a>

Malcolm Packer

Malcolm is Chief Executive Officer at Kidney Cancer UK and Kidney Cancer Scotland and has worked with the charity in various capacities for over 15 years.